Introduction Current issue Issue archive About the journal Editorial Board Subscription For authors and reviewers Contact us Česky
 
Login |
 
registration
   
have you forgotten your password?
 
send
 

Forum Diabetologicum

A diabetic patient with peripheral arterial disease

A diabetic patient with peripheral arterial disease

Diabetes mellitus and peripheral arterial disease frequently occur particularly at older age. Their simultaneous course presents a significant risk of vascular complications...

Authors: Tomáš Petrovič, Peter Jackuliak, Juraj Payer
Issue: 1/2018

Read article

Complex management of diabetic patients with lower extremity peripheral arterial disease

Complex management of diabetic patients with lower extremity peripheral arterial disease

Extremitovascular arterial ischemic disease (lower extremity peripheral arterial disease – PAD) is an important manifestation of systemic atherosclerosis and other arterial...

Authors: Peter Gavorník, Andrej Dukát, Ľudovít Gašpar, Gabriela Gubo, Naďa Bežillová, Martina Kováčová, Eva Gavorníková, Anna Petrášová, Iveta Gašparová, Lujza Sabolová, Marek Kučera, Katarína Kusendová, Alena Uhrinová, Matej Bendžala, Dáša Mesárošová
Issue: 1/2018

Read article

PCSK9 inhibitors and the role of evolocumab in the therapy for patients with hyperlipoproteinemia

PCSK9 inhibitors and the role of evolocumab in the therapy for patients with hyperlipoproteinemia

Relationship between LDL-cholesterol levels and cardiovascular risk is clear now­adays in the evidence-based medicine. Similarly also in the place of statins as the first line...

Authors: Andrej Dukát, Milan Kriška, P. Sabaka, P. Gavornik, M. Kužma, Juraj Payer
Issue: 1/2018

Read article

Vildagliptin: experience and prospects

Vildagliptin: experience and prospects

Vildagliptin is one of the modern antidiabetic drugs from the incretin group. It is a dipeptidyl peptidase-4 (DPP-4i) inhibitor, whose effectiveness and safety (including...

Issue: 1/2018

Read article

A consensual therapeutic recommendation for type 2 diabetes mellitus by the Slovak Diabetes Society (2018)

A consensual therapeutic recommendation for type 2 diabetes mellitus by the Slovak Diabetes Society (2018)

Type 2 diabetes mellitus is a heterogeneous medical condition involving multiple pathophysiological mechanisms. Its successful treatment requires an individualized approach and...

Authors: Emil Martinka, Vladimír Uličiansky, Marián Mokáň, Ivan Tkáč, Peter Galajda, Silvia Dókušová, Zbynek Schroner
Issue: 1/2018

Read article

Comprehensive approach in the management of patients with diabesity

Comprehensive approach in the management of patients with diabesity

Obesity is currently a global epidemic (pandemic) and the most common metabolic disorder affecting not only adults but also children and adolescents worldwide. Together with the...

Issue: 1/2018

Read article

Management of the patient with diabetes mellitus and hypertension

Management of the patient with diabetes mellitus and hypertension

Diabetes mellitus and hypertension represent important comorbidities, contribut­ing to the high mortality in this patient group. Therefore they are also called as the lethal...

Issue: 1/2018

Read article

Atrial fibrilation and diabetes mellitus

Atrial fibrilation and diabetes mellitus

Atrial fibrillation and diabetes mellitus are both highly prevalent and global public health issues. Importantly patients with diabetes mellitus are at increased risk for stroke...

Issue: 3/2017

Read article

Pharmacological management of diabetic dyslipidaemia

Pharmacological management of diabetic dyslipidaemia

Cardiovascular diseases are extremely common in type 2 diabetics. This is due to the presence of characteristic atherogenic dyslipidemia, which significantly contributes to...

Issue: 3/2017

Read article

Fourier Study: Has it brought little or a lot of good? Or has it just failed to reach exaggerated expectations?

Fourier Study: Has it brought little or a lot of good? Or has it just failed to reach exaggerated expectations?

The drugs of a novel class of hypolipidemic agents, PCSK9-inhibitors, are now approved for clinical use. In many EU countries, including Slovakia, these drugs are also available...

Issue: 3/2017

Read article

Subscription

Subscribe the Journal

The subscription grants you full access to all the articles.

further information

 

Issue No.: 1 / 2018

show contents

 

 

Most read